Synaffix, a Lonza company, announces the expansion of its licensing agreement with Innovent Biologics, a biopharmaceutical company that develops, manufactures and commercialises high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases. Building on...

Vesper Bio ApS announces that the first volunteer has been dosed with its lead compound VES001, a patient friendly, first-in-class, brain penetrant, oral treatment, that could bring a meaningful disease-modifying benefit to patients suffering from...